US6506766B1
(en)
*
|
1998-02-13 |
2003-01-14 |
Abbott Laboratories |
Glucocortiocoid-selective antinflammatory agents
|
US7026484B2
(en)
*
|
2001-02-23 |
2006-04-11 |
Ligand Pharmaceuticals Incorporated |
Tricyclic androgen receptor modulator compounds and methods
|
US6518430B1
(en)
*
|
2001-09-21 |
2003-02-11 |
Abbott Laboratories |
Process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-F]quinolines and derivatives thereof
|
CA2472746A1
(en)
*
|
2002-01-14 |
2003-07-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
|
ES2298508T3
(es)
*
|
2002-03-26 |
2008-05-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
|
CA2477764A1
(en)
*
|
2002-03-26 |
2003-10-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
DE60335869D1
(de)
*
|
2002-04-11 |
2011-03-10 |
Merck Sharp & Dohme |
1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
|
US7186864B2
(en)
|
2002-05-29 |
2007-03-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
US7074806B2
(en)
*
|
2002-06-06 |
2006-07-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
CA2496175A1
(en)
*
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
BR0313923A
(pt)
*
|
2002-08-29 |
2005-07-12 |
Boehringer Ingelheim Pharma |
Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
|
US20040220153A1
(en)
*
|
2002-09-24 |
2004-11-04 |
Jost-Price Edward Roydon |
Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
|
CA2501833A1
(en)
*
|
2002-10-11 |
2004-04-22 |
Ligand Pharmaceuticals Incorporated |
5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds
|
HK1055058A2
(en)
*
|
2002-10-11 |
2003-12-05 |
Ligand Pharm Inc |
5-CYCLOALKENYL 5H-CHROMENO[3,4-f]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
|
DE20301728U1
(de)
*
|
2002-10-11 |
2004-03-11 |
Ligand Pharmaceuticals, Inc., San Diego |
5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
|
EP1583745A1
(en)
*
|
2003-01-03 |
2005-10-12 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
|
US20040224992A1
(en)
*
|
2003-02-27 |
2004-11-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
US20070088042A1
(en)
*
|
2004-09-09 |
2007-04-19 |
Meissner Robert S |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
US7235662B2
(en)
|
2003-06-11 |
2007-06-26 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
US8097606B2
(en)
|
2003-07-23 |
2012-01-17 |
Corcept Therapeutics, Inc. |
Antiglucocorticoids for the treatment of catatonia
|
BRPI0413820A
(pt)
|
2003-08-22 |
2006-10-24 |
Ligand Pharm Inc |
derivados de 6-cicloamino-2-quinolinona como compostos moduladores de receptor de androgênio
|
UY28526A1
(es)
|
2003-09-24 |
2005-04-29 |
Boehringer Ingelheim Pharma |
Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7507843B2
(en)
*
|
2003-10-16 |
2009-03-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Stereoselective synthesis of certain trifluoromethyl-substituted alcohols
|
DE602004031356D1
(de)
|
2003-11-21 |
2011-03-24 |
Zalicus Inc |
Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
|
EP1718653A1
(en)
*
|
2004-02-25 |
2006-11-08 |
Ligand Pharmaceuticals Inc. |
Glucocorticoid receptor modulator compounds and methods- utility
|
WO2005090282A1
(en)
|
2004-03-12 |
2005-09-29 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
US7795272B2
(en)
*
|
2004-03-13 |
2010-09-14 |
Boehringer Ingelheim Pharmaceutical, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
JP2008525525A
(ja)
*
|
2004-12-27 |
2008-07-17 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドミメティクス、その製法、医薬組成物及び使用
|
ATE517908T1
(de)
|
2005-01-10 |
2011-08-15 |
Glaxo Group Ltd |
Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
PE20100741A1
(es)
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
EP1891067B1
(en)
*
|
2005-06-17 |
2016-01-13 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
NZ568694A
(en)
|
2005-11-09 |
2011-09-30 |
Zalicus Inc |
Method, compositions, and kits for the treatment of medical conditions
|
TW200730498A
(en)
|
2005-12-20 |
2007-08-16 |
Glaxo Group Ltd |
Compounds
|
EA200801997A1
(ru)
|
2006-04-20 |
2009-04-28 |
Глаксо Груп Лимитед |
Новые соединения
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
US20080161324A1
(en)
*
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
KR20090097908A
(ko)
*
|
2006-12-06 |
2009-09-16 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코코르티코이드 모사물, 이의 제조 방법, 이의 약제학적 조성물 및 용도
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
JP5791500B2
(ja)
|
2008-05-23 |
2015-10-07 |
パンミラ ファーマシューティカルズ,エルエルシー. |
5−リポキシゲナーゼ活性化タンパク質阻害剤
|
JP5502077B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
新規な化合物
|
ES2566339T3
(es)
|
2008-06-05 |
2016-04-12 |
Glaxo Group Limited |
Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
|
SI2300472T1
(sl)
*
|
2008-06-06 |
2012-05-31 |
Boehringer Ingelheim Int |
Glukokortikoidni mimetiki postopki za njihovo pripravo farmacevtski sestavki in njihove uporabe
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
JP5656880B2
(ja)
|
2009-03-09 |
2015-01-21 |
グラクソ グループ リミテッドGlaxo Group Limited |
Pi3キナーゼの阻害剤としての4−オキサジアゾール−2−イル−インダゾール
|
WO2010102968A1
(en)
|
2009-03-10 |
2010-09-16 |
Glaxo Group Limited |
Indole derivatives as ikk2 inhibitors
|
EP2408769A1
(en)
|
2009-03-17 |
2012-01-25 |
Glaxo Group Limited |
Pyrimidine derivatives used as itk inhibitors
|
US20120016011A1
(en)
|
2009-03-19 |
2012-01-19 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
CN102439151A
(zh)
|
2009-03-19 |
2012-05-02 |
默沙东公司 |
使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制
|
EP2408915A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
SG174581A1
(en)
|
2009-03-27 |
2011-10-28 |
Merck Sharp & Dohme |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
JP2012521764A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
|
EP2411019A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
WO2010122089A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as crac channel inhibitors
|
DK2899191T3
(da)
|
2009-04-30 |
2017-11-13 |
Glaxo Group Ltd |
Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
|
JP2013512880A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3−キナーゼ阻害剤としてのインダゾール誘導体
|
JP2013512879A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体
|
EP2507226A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Novel compounds
|
US20120272951A1
(en)
|
2009-12-16 |
2012-11-01 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
JP5876051B2
(ja)
|
2010-09-08 |
2016-03-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
|
RS54286B1
(en)
|
2010-09-08 |
2016-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
POLYMORPHS AND SALTS N- [5- [4- (5 - {[(2R, 6S) -2,6-DIMETHYL-4-MORPHOLINYL] METHYL} -1,3-OXAZOL-2-yl) -1H-INDAZZOL- 6-IL] -2 (methyloxy) -3-pyridinyl] -methanesulfonamide
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
JP5795643B2
(ja)
|
2010-10-21 |
2015-10-14 |
グラクソ グループ リミテッドGlaxo Group Limited |
アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
EP2683716A1
(en)
|
2011-03-11 |
2014-01-15 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
MY184292A
(en)
|
2013-09-22 |
2021-03-30 |
Sunshine Lake Pharma Co Ltd |
Substituted aminopyrimidine compounds and methods of use
|
CA2923995A1
(en)
|
2013-10-17 |
2015-04-23 |
Glaxosmithkline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
JP6475707B2
(ja)
|
2013-10-17 |
2019-02-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
呼吸器疾患の治療のためのpi3k阻害剤
|
CA2943979A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
WO2015173701A2
(en)
|
2014-05-12 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions for treating infectious diseases
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
EP3497100A1
(en)
|
2016-08-08 |
2019-06-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CN108530402B
(zh)
*
|
2018-04-10 |
2020-06-26 |
浙江工业大学 |
一种(R)-3-丙基-γ-丁内酯的制备方法
|
EP4125919A1
(en)
|
2020-03-26 |
2023-02-08 |
GlaxoSmithKline Intellectual Property Development Limited |
Cathepsin inhibitors for preventing or treating viral infections
|